Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Journal of Medical Economics|March 29, 2023
Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitorsMiguel Escobar, Neha Agrawal, Sagnik Chatterjee, et al.Journal of Medical Economics|March 11, 2026
Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatmentCamille N Kotton, Megan Richards, Nicole Princic, et al.Expert Review of Hematology|April 28, 2023
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitorsMiguel Escobar, Michael Bullano, Ali G Mokdad, et al.Current Medical Research and Opinion|July 26, 2022
A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumabKatharine Batt, Bob G Schultz, Jorge Caicedo, et al.Expert Review of Pharmacoeconomics & Outcomes Research|December 20, 2022
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia AMichael Bullano, Christina Cool, Bob G Schultz, et al.Allergy and Asthma Proceedings|July 10, 2024
Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world studyJohn Anderson, Daniel Soteres, Jennifer Mellor, et al.Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2022
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in FranceMark Oppe, Bogdan Muresan, Katie Chan, et al.The Journal of Allergy and Clinical Immunology. Global|June 22, 2026
Hereditary angioedema attack trends among patients maintained on lanadelumab long-term prophylaxisMaeve O'Connor, Joshua Jacobs, Laura Panattoni, et al.Allergy and Asthma Proceedings|March 17, 2026
Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxisMark Davis-Lorton, Daniel Soteres, William R Lumry, et al.International Archives of Allergy and Immunology|July 17, 2025
Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More YearsWilliam R Lumry, Mark Davis-Lorton, Daniel Soteres, et al.Pageof 3